

Shiqiao Ye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7913313/publications.pdf>

Version: 2024-02-01

22
papers

691
citations

623734

14
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1434
citing authors

#	ARTICLE	IF	CITATIONS
1	N-Cadherin Stabilizes β -Catenin and Promotes β -Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1572-1572.	1.4	0
2	Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4383-4383.	1.4	3
3	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. <i>BMC Cancer</i> , 2018, 18, 724.	2.6	26
4	Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma. <i>Blood</i> , 2018, 132, 3166-3166.	1.4	0
5	LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. <i>International Journal of Biological Sciences</i> , 2016, 12, 1488-1499.	6.4	10
6	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. <i>Blood</i> , 2016, 128, 2919-2930.	1.4	57
7	RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. <i>Cell Death and Disease</i> , 2016, 7, e2300-e2300.	6.3	16
8	PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. <i>JCI Insight</i> , 2016, 1, e86330.	5.0	57
9	The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition. <i>Blood</i> , 2016, 128, 1138-1138.	1.4	2
10	Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2. <i>Calcified Tissue International</i> , 2015, 96, 465-475.	3.1	30
11	Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in t(14;16) Multiple Myeloma. <i>Blood</i> , 2015, 126, 3020-3020.	1.4	1
12	Selective 14-3-3 β induction quenches p- β -catenin Ser37/Bax-enhanced cell death in cerebral cortical neurons during ischemia. <i>Cell Death and Disease</i> , 2014, 5, e1184-e1184.	6.3	24
13	Downregulation of Notch Modulators, Tetraspanin 5 and 10, Inhibits Osteoclastogenesis in Vitro. <i>Calcified Tissue International</i> , 2014, 95, 209-217.	3.1	50
14	Mafb Protein Confers Primary Resistance of Myeloma to Proteasome Inhibitors. <i>Blood</i> , 2014, 124, 2091-2091.	1.4	1
15	Disruption of the dynein-dynactin complex unveils motor-specific functions in osteoclast formation and bone resorption. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 119-134.	2.8	29
16	Suppression of Autophagy in Osteocytes Mimics Skeletal Aging. <i>Journal of Biological Chemistry</i> , 2013, 288, 17432-17440.	3.4	165
17	Steap4 Plays a Critical Role in Osteoclastogenesis in Vitro by Regulating Cellular Iron/Reactive Oxygen Species (ROS) Levels and cAMP Response Element-binding Protein (CREB) Activation. <i>Journal of Biological Chemistry</i> , 2013, 288, 30064-30074.	3.4	71
18	Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e74191.	2.5	39

#	ARTICLE	IF	CITATIONS
19	MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013, 122, 281-281.	1.4	1
20	LIS1 Regulates Osteoclast Formation and Function through Its Interactions with Dynein/Dynactin and Plekha7. <i>PLoS ONE</i> , 2011, 6, e27285.	2.5	42
21	Silencing neuroglobin enhances neuronal vulnerability to oxidative injury by down-regulating 14-3-3 σ . <i>Acta Pharmacologica Sinica</i> , 2009, 30, 913-918.	6.1	38
22	A simplified probe preparation for ELISA-based NF- κ B activity assay. <i>Journal of Proteomics</i> , 2005, 65, 20-29.	2.4	29